Neogen Chemicals Q1 FY27 Results (NSE: NEOGEN)
Signal: Margin expansion
The read
Q1 FY27 marks a strong start with revenue growth accelerating to +34% YoY (vs +21.7% in Q4 FY26) and EBITDA margin expanding 530bps to 20.8% — the highest in recent quarters — driven by favourable product mix and cost pass-throughs, despite the Dahej plant shutdown. PAT doubled to ₹17 Cr (+67% YoY). Battery chemicals subsidiary Neogen Ionics posted ₹19 Cr revenue (tripling YoY), signalling ramp-up. Key overhang: finance costs surged 64% YoY on capex-related debt; QIP of up to ₹600 Cr approved to address leverage.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹250.29 Cr | 34.0% | -71.0% |
| EBIT | ₹43.89 Cr | 63.1% | |
| Net profit | ₹17 Cr | 67% | |
| EPS | ₹6.29 | 61.7% | |
| EBIT margin | 20.8% |
P&L walk
Revenue grew 34% YoY driven by volume gains across Organolithium, Inorganic Chemicals, and Battery Chemicals (Neogen Ionics revenue tripled). Gross profit +37% YoY. EBITDA grew 53% YoY, margin expanded 530bps to 20.8% on favourable product mix and cost pass-throughs despite Dahej plant shutdown and toll manufacturing costs. EBIT +63.1% YoY. PAT +67% YoY, partly offset by finance costs +64% YoY. EPS +61.7% YoY, tracking PAT.
Segments
No segment table disclosed; the filing notes Organolithium and Inorganic Chemicals drove volume growth, while Neogen Ionics (battery chemicals subsidiary) contributed ₹19 Cr revenue (vs ₹5 Cr in Q1 FY26).
Key positives
- Revenue ₹250 Cr (+34% YoY) — fastest growth in 5 quarters, volume-led across all product lines.
- EBITDA margin expanded 530bps YoY to 20.8% — highest in recent history — on favourable product mix and cost pass-throughs.
- PAT ₹17 Cr (+67% YoY) — more than doubled; EPS ₹6.29 (+61.7% YoY).
- Neogen Ionics revenue tripled to ₹19 Cr, generating over 50% of its prior full-year revenue in Q1 alone.
- Board approved QIP up to ₹600 Cr to strengthen balance sheet for capex.
Key concerns
- Finance costs up 64% YoY due to higher debt for capex and working capital inflation — interest coverage remains a monitorable.
- Gross block growth from battery capex may pressure depreciation in coming quarters.
- Dahej replacement plant still in trial runs — commercial production yet to commence.
Research and educational content only. Not investment advice.